Canada Markets open in 2 hrs 48 mins

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.14+0.22 (+2.01%)
At close: 04:00PM EST
11.25 +0.11 (+0.99%)
After hours: 07:14PM EST

Atai Life Sciences N.V.

Krausenstrasse 9-10
Berlin 10117
49 89 2153 9035

Full Time Employees35

Key Executives

NameTitlePayExercisedYear Born
Mr. Florian BrandCo-Founder, MD & CEO405.02kN/A1987
Dr. Srinivas G. RaoCo-Founder & Chief Scientific Officer535.03kN/A1969
Mr. Gregory L. Weaver CPA, M.B.A.MD & CFO479.71kN/A1956
Mr. Christian AngermayerFounderN/AN/A1978
Mr. Lars Christian WildeCo-FounderN/AN/A1986
Ms. Maddy CrawfordMang. of AccountingN/AN/AN/A
Mr. Josh ElliottMang. of MarketingN/AN/AN/A
Dr. Rolando Gutierrez-Esteinou M.D.Chief Medical OfficerN/AN/A1961
Ms. Anna RichardsonChief of Staff & Lead of Stakeholder EngagementN/AN/AN/A
Ms. Anne JohnsonLead of Global ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Corporate Governance

Atai Life Sciences N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.